RHHBY - Roche Holding AG

Other OTC - Other OTC Delayed Price. Currency in USD
34.55
-0.17 (-0.49%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close34.72
Open34.58
Bid0.00 x 0
Ask0.00 x 0
Day's Range34.51 - 34.72
52 Week Range26.35 - 34.98
Volume357,730
Avg. Volume1,065,844
Market Cap233.509B
Beta (3Y Monthly)0.42
PE Ratio (TTM)22.50
EPS (TTM)1.54
Earnings DateN/A
Forward Dividend & Yield1.07 (3.27%)
Ex-Dividend Date2019-03-07
1y Target Est37.90
Trade prices are not sourced from all markets
  • Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures
    Investor's Business Daily2 days ago

    Why Alzheimer's Treatment Hopes Endure Despite High-Profile Drug Failures

    Alzheimer's treatment continues to confound biotech companies in the wake of Biogen and Eisai's decision to terminate two late-stage tests. But scientists say there's hope in new theories.

  • Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod
    Zacks2 days ago

    Pharma Stock Roundup: MRK Buys Small Cancer Biotech, RHHBY, MRK Drugs Get FDA Nod

    Key developments of the week include Merck's (MRK) deal to buy Tilos Therapeutics and FDA approval for Roche's (RHHBY) polatuzumab vedotin and Merck's Keytruda.

  • Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti
    Zacks2 days ago

    Amgen/Allergan Get FDA Nod for Herceptin Biosimilar Kanjinti

    FDA approves Amgen (AMGN) and Allergan's Kanjiniti, a biosimilar version of Roche's (RHHBY) breast cancer drug, Herceptin.

  • Mallinckrodt Presents Encouraging Data on Acthar Gel for RA
    Zacks2 days ago

    Mallinckrodt Presents Encouraging Data on Acthar Gel for RA

    Mallinckrodt (MNK) reports encouraging results from a phase IV study on Acthar for RA at the EULAR.

  • Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris
    Zacks3 days ago

    Roche Reports Positive Data on Rituxan for Pemphigus Vulgaris

    Roche (RHHBY) announces positive data on rheumatic diseases drug, Rituxan, for pemphigus vulgaris.

  • Benzinga3 days ago

    The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 12) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp ...

  • Barrons.com3 days ago

    A Stock Fund Challenges the Definition of Growth. It’s Paying Off.

    Elisa Mazen, who co-manages the $1.6 billion ClearBridge International Growth fund, isn’t afraid to take a broad definition of growth to find the best opportunities.

  • Business Wire3 days ago

    Phase III PEMPHIX Study Showed That Genentech’s Rituxan (Rituximab) is Superior to Standard of Care in Achieving Sustained Remission in Patients with Pemphigus Vulgaris

    OTCQX: RHHBY), today announced positive top line results from the Roche-sponsored Phase III PEMPHIX study evaluating the efficacy and safety of Rituxan® (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris (PV). The study met the primary endpoint, and demonstrated that Rituxan is superior to MMF in achieving sustained complete remission.

  • Roche's Rituxan Gets Priority Review for Blood Disorder
    Zacks4 days ago

    Roche's Rituxan Gets Priority Review for Blood Disorder

    Roche (RHHBY) gets Priority Review status from the FDA for Rituxan in children with two rare blood vessel disorders.

  • Boost Your Portfolio's Health With These 3 Big Drug Stocks
    Zacks4 days ago

    Boost Your Portfolio's Health With These 3 Big Drug Stocks

    The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.

  • Benzinga4 days ago

    The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 11) BIOFRONTERA AG/ADR (NASDAQ: BFRA ) BIO-TECHNE Corp ...

  • Business Wire4 days ago

    FDA Grants Priority Review to Genentech’s Rituxan (Rituximab) in Children with Two Rare Blood Vessel Disorders

    SOUTH SAN FRANCISCO, Calif.-- -- There are currently no FDA approved treatments for children living with granulomatosis with polyangiitis or microscopic polyangiitis The PePRS study is the first global trial of Rituxan in pediatric patients with GPA or MPA Rituxan in combination with glucocorticoids is the only FDA-approved therapy for adults with these two rare forms of vasculitis If approved, this ...

  • Insys Down on Bankruptcy News Amid Increasing Legal Expenses
    Zacks5 days ago

    Insys Down on Bankruptcy News Amid Increasing Legal Expenses

    Insys (INSY) crashes as it files for bankruptcy protection amid rising legal settlement dues.

  • Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II
    Zacks5 days ago

    Roche's Polivy Gets FDA Nod, Gazyva Meets Goals in Phase II

    Roche's (RHHBY) hematology portfolio gets a boost as FDA approves Polivy for DLBCL, and lymphoma drug, Gazyva, meets goals in a phase II study.

  • Roche names new head of $13 billion diagnostics unit
    Reuters5 days ago

    Roche names new head of $13 billion diagnostics unit

    Swiss drugmaker Roche on Tuesday named a new head of its $13-billion-per-year diagnostics business and also said board member Peter Voser is stepping down to focus on his expanded duties as interim head of Swiss engineering group ABB. Roche's new diagnostics boss, Thomas Schinecker, fills a post that had been led for months on an interim basis by Michael Heuer, who is retiring. Roche's diagnostics unit includes diabetes care, sophisticated laboratory equipment and tests aimed at personalizing cancer treatment.

  • GlobeNewswire5 days ago

    FDA grants Roche’s Polivy accelerated approval for people with previously treated aggressive lymphoma

    OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Polivy™ (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least two prior therapies. Accelerated approval was granted for this indication based on complete response rates observed in a randomised, controlled clinical trial.

  • Business Wire5 days ago

    Genentech’s Gazyva (Obinutuzumab) Delivers Positive Topline Results for Phase II Lupus Nephritis Study

    OTCQX: RHHBY), today announced positive topline results for NOBILITY, a Phase II clinical trial investigating the safety and efficacy of Gazyva® (obinutuzumab) for adults with proliferative lupus nephritis. The study met its primary endpoint, showing Gazyva, in combination with standard of care (mycophenolate mofetil or mycophenolic acid and corticosteroids), demonstrated enhanced efficacy compared to placebo plus standard of care alone in achieving complete renal response at one year. In addition, Gazyva met key secondary endpoints showing improved overall renal responses (complete and partial renal response) and serologic markers of disease activity as compared to placebo.

  • GlobeNewswire5 days ago

    Changes in Roche's Board of Directors and Corporate Executive Committee

    OTCQX: RHHBY) today announced that Peter Voser (61), a member of the Board of Directors of Roche Holding Ltd since 2011, has decided to step down as a member of the Board of Directors of Roche at the end of June 2019 due to his additional role as interim CEO of ABB. Roche Chairman Christoph Franz: "Peter Voser has made important contributions to Roche's success as a member of the Board and the Compensation Committee.

  • Roche's $4.8 Billion Buyout Of Spark Delayed Amid Competitive Worries
    Investor's Business Daily6 days ago

    Roche's $4.8 Billion Buyout Of Spark Delayed Amid Competitive Worries

    Spark Therapeutics stock tumbled Monday after Swiss biopharma Roche delayed its $4.8 billion takeover of the biotech as regulators in the U.S. and Europe scrutinized the transaction.

  • Benzinga6 days ago

    Roche Extends Deadline For Spark Acquisition As US, UK Regulators Seek Additional Information

    The expiration date of Roche's offer has been extended from 5 p.m. Friday, June 14 to 5 p.m. July 31, which suggests Spark shareholders now have until July 31 to tender their shares. Roche has a lot riding on the Spark deal given the pharma giant's recent focus on gene therapies. Spark already has an approved gene therapy, Luxturna, for inherited retinal disease, and more investigational therapies in the pipeline for hemophilia A, hemophilia B, lysosomal storage disorders and neurodegenerative diseases.

  • MarketWatch6 days ago

    FDA approves Genentech's Polivy as part of first chemoimmunotherapy regimen for patients with diffuse large B-cell lymphoma

    The U.S. Food and Drug Administration said Monday it had approved the first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma: A combination of Genentech's Polivy, the chemotherapy bendamustine and a rituximab product. Genentech, a subsidiary of Roche Holding AG , was granted accelerated approval based on the results of a Phase 1b/2 randomized clinical trial that showed that patients on a combination of Polivy (polatuzumab vedotin-piiq), bendamustine and rituximab showed better response rates than those on just bendamustine and rituximab. "Despite meaningful progress in the treatment of diffuse large B-cell lymphoma, treatment options are very limited when the disease is refractory to or recurrent after multiple regimens," Sandra Horning, chief medical officer and head of Global Product Development at Genentech, said in a statement. "Today's approval of this Polivy combination will provide a novel treatment that is both immediately available and very much needed for people with this aggressive disease." Shares of Roche have gained 10.2% in the year to date, while the S&P 500 has gained 15.3%.

  • Reuters6 days ago

    CORRECTED-UPDATE 3-Roche's combo lymphoma treatment wins U.S. FDA approval

    The U.S. Food and Drug Administration on Monday granted earlier-than-expected approval to Roche Holding AG's antibody- Polivy for treatment of patients with advanced lymphoma. Polivy was approved in combination with Roche's older drug Rituxan and a chemotherapy agent for adult patients with advanced diffuse large B-cell lymphoma (DLBCL) whose cancer has worsened despite at least two previous lines of therapy. Antibody-drug conjugates are designed to deliver a toxic chemotherapy directly to tumors.

  • Business Wire6 days ago

    FDA Grants Genentech’s Polivy Accelerated Approval for People with Previously Treated Aggressive Lymphoma

    OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Polivy™ (polatuzumab vedotin-piiq) in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of adults with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least two prior therapies. Accelerated approval was granted for this indication based on complete response rates observed in a randomized, controlled clinical trial.